Video
Dr. Kornblum on Results of PrECOG 0102 in Breast Cancer
Author(s):
Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.
Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.
The primary endpoint of the PrECOG 0102 study was progression-free survival (PFS). It was found that the combination of everolimus and fulvestrant doubled PFS from 5.1 months to 10.4 months. This has been consistent with the type of response seen in the BOLERO-2 trial looking at everolimus in combination with exemestane.
Fulvestrant alone had a PFS of 5.1 months, suggesting that in the aromatase inhibitor-resistant population, fulvestrant might be more beneficial to combine with everolimus, explains Kornblum.
